Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies (Pituitary, (2025), 28, 1, (22), 10.1007/s11102-024-01471-3)

Abstract

In the original publication of the article, the authors have found two errors in Fig. 2, as follows: In Fig. 2C, the definition of diabetes based on FPG levels in the figure key is currently ≤ 126 mg/dL (≤ 7.0 mmol/L); however, this should be ≥ 126 mg/dL (≥ 7.0 mmol/L). In Fig. 2D, the definition of normal HbA1c levels in the figure key is currently ≥ 47.5 mmol/mol; however, this should be < 47.5 mmol/mol. Mean (a) FPG and (b) HbA1c over time in patients with and without diabetes at baseline. Shift over time in (c) FPG in patients with high FPG (≥ 100 mg/dL) at baseline and (d) HbA1c in patients with high HbA1c (≥ 6.5%) at baseline. Mean (e) FPG and (f) HbA1c over time in patients with diabetes at baseline, according to antihyperglycemic medication use during the studies. For panels a and e, the dashed gray lines indicate the FPG thresholds for pre-diabetes (100 mg/dL [5.6 mmol/L]) and diabetes (126 mg/dL [7.0 mmol/L]). For panels b and f, the dashed gray lines indicate the HbA1c threshold for diabetes (6.5% [47.5 mmol/mol]) Hence, the corrected Fig. 2 is given below: Mean (a) FPG and (b) HbA1c over time in patients with and without diabetes at baseline. Shift over time in (c) FPG in patients with high FPG (≥ 100 mg/dL) at baseline and (d) HbA1c in patients with high HbA1c (≥ 6.5%) at baseline. Mean (e) FPG and (f) HbA1c over time in patients with diabetes at baseline, according to antihyperglycemic medication use during the studies. For panels a and e, the dashed gray lines indicate the FPG thresholds for pre-diabetes (100 mg/dL [5.6 mmol/L]) and diabetes (126 mg/dL [7.0 mmol/L]). For panels b and f, the dashed gray lines indicate the HbA1c threshold for diabetes (6.5% [47.5 mmol/mol]) The original article has been corrected.